MediciNova Inc. (MNOV)
1.45
0.00 (0.00%)
At close: Apr 17, 2025, 3:59 PM
1.45
0.00%
After-hours: Apr 17, 2025, 04:00 PM EDT
0.00% (1D)
| Bid | 1.11 |
| Market Cap | 71.12M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -2.86B |
| EPS (ttm) | -0.23 |
| PE Ratio (ttm) | -6.3 |
| Forward PE | n/a |
| Analyst | Buy |
| Ask | 1.75 |
| Volume | 6,458 |
| Avg. Volume (20D) | 16,746 |
| Open | 1.39 |
| Previous Close | 1.45 |
| Day's Range | 1.45 - 1.45 |
| 52-Week Range | 1.12 - 2.55 |
| Beta | 0.75 |
About MNOV
MediciNova, Inc., a biopharmaceutical company, focuses on developing novel and small molecule therapeutics for the treatment of serious diseases with unmet medical needs in the United States. The company is developing MN-166 (ibudilast), an oral anti-inflammatory and neuroprotective agent for treating neurological disorders, such as primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced periphera...
Industry Biotechnology
Sector Healthcare
IPO Date Dec 8, 2006
Employees 13
Stock Exchange NASDAQ
Ticker Symbol MNOV
Website https://www.medicinova.com
Analyst Forecast
According to 1 analyst ratings, the average rating for MNOV stock is "Buy." The 12-month stock price forecast is $9, which is an increase of 520.69% from the latest price.
Stock Forecasts4 months ago
+14.98%
MediciNova shares are trading higher after D. Bora...
Unlock content with
Pro Subscription
5 months ago
+49.02%
MediciNova shares are trading higher after the company announced that it was notified by Sanofi that the Sanofi/Novartis litigation was settled.
